A 59-year-old with diabetes and CKD G4 (eGFR 25) asks whether to continue SGLT2 inhibitor. He is euvolemic. Albuminuria 900 mg/g. What do guidelines a...

Question

A 59-year-old with diabetes and CKD G4 (eGFR 25) asks whether to continue SGLT2 inhibitor. He is euvolemic. Albuminuria 900 mg/g. What do guidelines advise?

Accepted Answer

Continue SGLT2 inhibitor down to eGFR ≥20 mL/min/1.73 m² for kidney/CV benefit if tolerated

Answer

Stop SGLT2 inhibitor when eGFR

Answer

Stop all RAS blockade at eGFR 25

Answer

Start dual RAS blockade

Answer

SGLT2 inhibitors have no benefit without diabetes

us-abim MCQ (SBA): CKD - SGLT2 Use

A 59-year-old with diabetes and CKD G4 (eGFR 25) asks whether to continue SGLT2 inhibitor. He is euvolemic. Albuminuria 900 mg/g. What do guidelines advise?